5.69
0.92 (19.29%)
| Previous Close | 4.77 |
| Open | 5.00 |
| Volume | 514,657,848 |
| Avg. Volume (3M) | 113,347,603 |
| Market Cap | 101,815,148,544 |
| Price / Earnings (TTM) | 51.73 |
| Price / Earnings (Forward) | 29.59 |
| Price / Sales | 2.99 |
| Price / Book | 2.65 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| TTM Dividend Yield | 1.26% |
| Profit Margin | 12.12% |
| Operating Margin (TTM) | 13.08% |
| Diluted EPS (TTM) | 0.110 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | 139.70% |
| Total Debt/Equity (MRQ) | 22.70% |
| Current Ratio (MRQ) | 1.26 |
| Operating Cash Flow (TTM) | 6.62 B |
| Levered Free Cash Flow (TTM) | 3.90 B |
| Return on Assets (TTM) | 5.62% |
| Return on Equity (TTM) | 11.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | SINO BIOPHARM | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.25 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| SINO BIOPHARM | 102 B | 1.26% | 51.73 | 2.65 |
| WUXI BIO | 104 B | - | 30.18 | 2.24 |
| PHARMARON | 47 B | 1.23% | 15.04 | 1.88 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
| AKESO | 88 B | - | - | 11.02 |
| BEIGENE | 221 B | - | - | 8.31 |
|
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 48.22% |
| % Held by Institutions | 16.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |